Zolmitriptan en es it fr

Zolmitriptan Brand names, Zolmitriptan Analogs

Zolmitriptan Brand Names Mixture

  • No information avaliable

Zolmitriptan Chemical_Formula


Zolmitriptan RX_link


Zolmitriptan fda sheet

Zolmitriptan FDA

Zolmitriptan msds (material safety sheet)

Zolmitriptan Synthesis Reference

No information avaliable

Zolmitriptan Molecular Weight

287.357 g/mol

Zolmitriptan Melting Point

No information avaliable

Zolmitriptan H2O Solubility

No information avaliable

Zolmitriptan State


Zolmitriptan LogP


Zolmitriptan Dosage Forms

Spray; Tablet

Zolmitriptan Indication

For the acute treatment of adult migraine (with or without auras)

Zolmitriptan Pharmacology

Zolmitriptan is a selective 5-hydroxytryptamine receptor subtype agonist indicated for the acute treatment of migraine attacks with or without aura in adults. Zolmitriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Zolmitriptan is an agonist for a vascular 5-hydroxytryptamine receptor subtype (probably a member of the 5-HT1D family) having only a weak affinity for 5-HT1A, 5-HT5A, and 5-HT7 receptors and no significant affinity or pharmacological activity at 5-HT2, 5-HT3 or 5-HT4 receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Zolmitriptan also activates 5-HT1 receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Zolmitriptan in humans.

Zolmitriptan Absorption


Zolmitriptan side effects and Toxicity

No information avaliable

Zolmitriptan Patient Information

No information avaliable

Zolmitriptan Organisms Affected

Humans and other mammals